

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/074123 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 37/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2021/077702
- (22) **International Filing Date:**
07 October 2021 (07.10.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/089,355 08 October 2020 (08.10.2020) US
63/178,748 23 April 2021 (23.04.2021) US
- (71) **Applicant:** **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).
- (72) **Inventors:** **KALYANI, Rubana**; MedImmune, LLC One MedImmune Way, MD, Gaithersburg 20878 (US). **ABREU, Gabriel**; AstraZeneca AB, SE-151 85 Södertälje (SE). **TUMMALA, Rajendra**; AstraZeneca Pharmaceuticals LP 1800 Concord Pike, PO Box 15437, Wilmington, Delaware 19850-5437 (US). **FURIE, Richard**; Northwell Health, Inc North Shore University Hospital, Manhasset, New York 11030 (US). **MORAND, Eric**; Monash Health, Centre for Inflammatory Disease Monash University, Clayton, VIC (AU). **ASKANASE, Anca**; The Trustees of Columbia University in the City of New York 412 Low Memorial Library, 535 West 116th street, New York, NY 10027 (US). **VITAL, Ed**; Leeds University NIHR Leeds Biomedical Research Centre at Leeds Teaching Hospitals NHS

Trust, Leeds (GB). **KALUNIAN, Kenneth**; University of California San Diego Health, La Jolla, CA (US). **LINDHOLM, Catharina**; AstraZeneca AB, SE-151 85 Södertälje (SE). **MAHO, Emmanuelle**; AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **KLEOUDIS, Christi**; AstraZeneca Pharmaceuticals LP 1800 Concord Pike, PO Box 15437, Wilmington, Delaware 19850-5437 (US).


(74) **Agent:** **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** TREATMENT OF FLARES IN LUPUS

FIG. 2A



(57) **Abstract:** The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). The disclosure particular relates to the treatment of flares in SLE across multiple organ domains.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*